CELC
Price
$14.40
Change
+$0.16 (+1.12%)
Updated
Sep 27 closing price
39 days until earnings call
EDIT
Price
$3.48
Change
-$0.01 (-0.29%)
Updated
Sep 27 closing price
38 days until earnings call
Ad is loading...

CELC vs EDIT

Header iconCELC vs EDIT Comparison
Open Charts CELC vs EDITBanner chart's image
Celcuity
Price$14.40
Change+$0.16 (+1.12%)
Volume$101.98K
CapitalizationN/A
Editas Medicine
Price$3.48
Change-$0.01 (-0.29%)
Volume$2.06M
CapitalizationN/A
View a ticker or compare two or three
CELC vs EDIT Comparison Chart
Loading...
CELC
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
EDIT
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
VS
CELC vs. EDIT commentary
Sep 29, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CELC is a Sell and EDIT is a Hold.

COMPARISON
Comparison
Sep 29, 2024
Stock price -- (CELC: $15.62 vs. EDIT: $3.49)
Brand notoriety: CELC and EDIT are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CELC: 40% vs. EDIT: 106%
Market capitalization -- CELC: $533.23M vs. EDIT: $287.02M
CELC [@Biotechnology] is valued at $533.23M. EDIT’s [@Biotechnology] market capitalization is $287.02M. The market cap for tickers in the [@Biotechnology] industry ranges from $531.37B to $0. The average market capitalization across the [@Biotechnology] industry is $3.01B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CELC’s FA Score shows that 0 FA rating(s) are green whileEDIT’s FA Score has 1 green FA rating(s).

  • CELC’s FA Score: 0 green, 5 red.
  • EDIT’s FA Score: 1 green, 4 red.
According to our system of comparison, CELC is a better buy in the long-term than EDIT.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CELC’s TA Score shows that 6 TA indicator(s) are bullish while EDIT’s TA Score has 3 bullish TA indicator(s).

  • CELC’s TA Score: 6 bullish, 4 bearish.
  • EDIT’s TA Score: 3 bullish, 6 bearish.
According to our system of comparison, CELC is a better buy in the short-term than EDIT.

Price Growth

CELC (@Biotechnology) experienced а -7.63% price change this week, while EDIT (@Biotechnology) price change was -8.64% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +3.80%. For the same industry, the average monthly price growth was +5.34%, and the average quarterly price growth was -8.06%.

Reported Earning Dates

CELC is expected to report earnings on Nov 07, 2024.

EDIT is expected to report earnings on Nov 06, 2024.

Industries' Descriptions

@Biotechnology (+3.80% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CELC($533M) has a higher market cap than EDIT($287M). CELC YTD gains are higher at: 7.207 vs. EDIT (-65.548).
CELCEDITCELC / EDIT
Capitalization533M287M186%
EBITDAN/AN/A-
Gain YTD7.207-65.548-11%
P/E RatioN/AN/A-
RevenueN/AN/A-
Total CashN/AN/A-
Total DebtN/AN/A-
FUNDAMENTALS RATINGS
CELC vs EDIT: Fundamental Ratings
CELC
EDIT
OUTLOOK RATING
1..100
7159
VALUATION
overvalued / fair valued / undervalued
1..100
45
Fair valued
25
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9797
PRICE GROWTH RATING
1..100
4692
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

EDIT's Valuation (25) in the Biotechnology industry is in the same range as CELC (45) in the Miscellaneous Commercial Services industry. This means that EDIT’s stock grew similarly to CELC’s over the last 12 months.

EDIT's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as CELC (100) in the Miscellaneous Commercial Services industry. This means that EDIT’s stock grew similarly to CELC’s over the last 12 months.

EDIT's SMR Rating (97) in the Biotechnology industry is in the same range as CELC (97) in the Miscellaneous Commercial Services industry. This means that EDIT’s stock grew similarly to CELC’s over the last 12 months.

CELC's Price Growth Rating (46) in the Miscellaneous Commercial Services industry is somewhat better than the same rating for EDIT (92) in the Biotechnology industry. This means that CELC’s stock grew somewhat faster than EDIT’s over the last 12 months.

CELC's P/E Growth Rating (100) in the Miscellaneous Commercial Services industry is in the same range as EDIT (100) in the Biotechnology industry. This means that CELC’s stock grew similarly to EDIT’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CELCEDIT
RSI
ODDS (%)
Bullish Trend about 1 month ago
0%
Bullish Trend about 1 month ago
0%
Stochastic
ODDS (%)
Bearish Trend about 1 month ago
0%
Bullish Trend about 1 month ago
0%
Momentum
ODDS (%)
Bullish Trend about 1 month ago
0%
Bearish Trend about 1 month ago
0%
MACD
ODDS (%)
Bearish Trend about 1 month ago
0%
Bearish Trend about 1 month ago
0%
TrendWeek
ODDS (%)
Bullish Trend about 1 month ago
0%
Bullish Trend about 1 month ago
0%
TrendMonth
ODDS (%)
Bearish Trend about 1 month ago
0%
Bearish Trend about 1 month ago
0%
Advances
ODDS (%)
Bullish Trend about 1 month ago
0%
N/A
Declines
ODDS (%)
Bearish Trend about 2 months ago
0%
Bearish Trend about 2 months ago
87%
BollingerBands
ODDS (%)
Bullish Trend about 1 month ago
0%
Bullish Trend about 1 month ago
0%
Aroon
ODDS (%)
Bullish Trend about 1 month ago
0%
Bearish Trend about 1 month ago
0%
View a ticker or compare two or three
Ad is loading...
CELC
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
EDIT
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
GME23.14-0.28
-1.20%
GameStop Corp
TSLA210.60-3.51
-1.64%
Tesla
SPY552.08-11.60
-2.06%
SPDR® S&P 500® ETF Trust
AAPL222.77-6.23
-2.72%
Apple
BTC.X57431.023000-1681.457000
-2.84%
Bitcoin cryptocurrency

CELC and

Correlation & Price change

A.I.dvisor indicates that over the last year, CELC has been loosely correlated with NTLA. These tickers have moved in lockstep 36% of the time. This A.I.-generated data suggests there is some statistical probability that if CELC jumps, then NTLA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CELC
1D Price
Change %
CELC100%
-2.13%
NTLA - CELC
36%
Loosely correlated
-3.65%
ALLO - CELC
36%
Loosely correlated
-4.56%
SNDX - CELC
35%
Loosely correlated
-0.05%
EDIT - CELC
35%
Loosely correlated
-6.68%
QSI - CELC
34%
Loosely correlated
-4.94%
More

EDIT and

Correlation & Price change

A.I.dvisor indicates that over the last year, EDIT has been closely correlated with NTLA. These tickers have moved in lockstep 74% of the time. This A.I.-generated data suggests there is a high statistical probability that if EDIT jumps, then NTLA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To EDIT
1D Price
Change %
EDIT100%
-6.68%
NTLA - EDIT
74%
Closely correlated
-3.65%
CRSP - EDIT
67%
Closely correlated
-4.61%
BEAM - EDIT
66%
Closely correlated
-8.55%
PRME - EDIT
54%
Loosely correlated
-9.81%
ALLO - EDIT
52%
Loosely correlated
-4.56%
More